Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis

[1]  Brian L. Shaw,et al.  Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases , 2021, Nature Communications.

[2]  D. de Ruysscher,et al.  Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. , 2019, European journal of cancer.

[3]  M. J. van den Bent,et al.  How we treat patients with leptomeningeal metastases , 2019, ESMO Open.

[4]  A. Awada.  Faculty Opinions recommendation of Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[5]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[6]  C. Bettegowda,et al.  Current state of immunotherapy for glioblastoma , 2018, Nature Reviews Clinical Oncology.

[7]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[8]  A. Melcher,et al.  Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking , 2018, Proceedings of the National Academy of Sciences.

[9]  P. Brastianos,et al.  Leptomeningeal metastasis from systemic cancer: Review and update on management , 2018, Cancer.

[10]  L. Dirix,et al.  Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study , 2017, Breast Cancer Research and Treatment.

[11]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[12]  S. Loi,et al.  Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis , 2016, Breast Cancer Research.

[13]  S. Loi,et al.  Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis , 2016, Breast Cancer Research.

[14]  Naoya Hashimoto,et al.  NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP , 2015 .

[15]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[16]  C. Villarreal-Garza,et al.  Clinical Features and Prognostic Factors in Patients with Carcinomatous Meningitis Secondary to Breast Cancer , 2012, The breast journal.

[17]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[18]  M. Chamberlain.  Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series , 2012, Journal of Neuro-Oncology.

[19]  P. Beauchesne.  Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. , 2010, The Lancet. Oncology.

[20]  M. Chamberlain,et al.  Leptomeningeal Metastasis , 2010, Seminars in neurology.

[21]  J. Shih,et al.  Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. , 2008, Journal of the Formosan Medical Association = Taiwan yi zhi.

[22]  M. Høyer,et al.  [Meningeal carcinomatosis]. , 2005, Ugeskrift for laeger.

[23]  B. Doebbeling,et al.  Meningeal carcinomatosis from breast cancer: Spinal cord vs. brain involvement , 2005, Breast Cancer Research and Treatment.

[24]  S. Grossman,et al.  Leptomeningeal carcinomatosis. , 1999, Cancer treatment reviews.

[25]  M. Chamberlain,et al.  Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. , 1997, Journal of neurosurgery.

[26]  D. Ettinger,et al.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. P. Glass,et al.  Leptomeningeal metastasis , 1993, Neurology.

[28]  A. Hart,et al.  Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma , 1983, Neurology.

[29]  R. Makuch,et al.  Carcinomatous Leptomeningitis in Small Cell Lung Cancer: A Clinicopathologic Review of the National Cancer Institute Experience , 1982, Medicine.

[30]  J. Adams,et al.  Diffuse involvement of the leptomeninges by tumour--a clinical and pathological study of 63 cases. , 1980, Postgraduate medical journal.

[31]  A. J. Dale,et al.  Meningeal carcinomatosis. Clinical manifestations. , 1974, Archives of neurology.